Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cancer survivor preferences on the timing and content of interventions to mitigate financial toxicity associated with cancer treatment.
Huq MR, Schwartz MD, Derry-Vick H, Khoudary A, Sorgen L, Billini O, Gunning TS, Luck C, Kaushik S, Hurley VB, Marshall J, Weinberg BA, Tesfaye A, Ip A, Potosky AL, Conley CC. Huq MR, et al. Among authors: ip a. Support Care Cancer. 2024 Nov 8;32(12):778. doi: 10.1007/s00520-024-08983-5. Support Care Cancer. 2024. PMID: 39511025
Prevalence of non-Hodgkin lymphoma patients at high-risk of failure after CAR T-cell therapy eligible for bridging radiation therapy.
Danish A, Della Pia A, Fogel L, Alkhatatneh H, Zhao C, Varughese T, Al Feghali KA, Pascual L, Sinclaire B, Marafelias M, Zenreich J, Kuo YH, Feldman TA, Zhang Y, Goy AH, Ip A, Rowley SD. Danish A, et al. Among authors: ip a. Front Oncol. 2024 Aug 19;14:1425506. doi: 10.3389/fonc.2024.1425506. eCollection 2024. Front Oncol. 2024. PMID: 39228984 Free PMC article.
Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma.
Rosenthal A, Munoz J, Jun M, Wang T, Mutebi A, Wang A, Yang S, Osei-Bonsu K, Elliott B, Rivas Navarro F, Yu J, Brodkin S, Sacchi M, Ip A. Rosenthal A, et al. Among authors: ip a. J Hematol Oncol. 2024 Aug 16;17(1):69. doi: 10.1186/s13045-024-01594-x. J Hematol Oncol. 2024. PMID: 39152509 Free PMC article.
Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma.
Lorenc R, Shouval R, Flynn JR, Devlin SM, Saldia A, De Abia AL, De Lapuerta MC, Tomas AA, Cassanello G, Leslie LA, Rejeski K, Lin RJ, Scordo M, Shah GL, Palomba ML, Salles G, Park J, Giralt SA, Perales MA, Ip A, Dahi PB. Lorenc R, et al. Among authors: ip a. Transplant Cell Ther. 2024 Oct;30(10):990-1000. doi: 10.1016/j.jtct.2024.06.027. Epub 2024 Jul 6. Transplant Cell Ther. 2024. PMID: 38972512
Clinical Outcomes of Immune Checkpoint Inhibitors in Unique Cohorts Underrepresented in Clinical Trials.
Shah NJ, Della Pia A, Wu T, Williams A, Weber M, Sinclaire B, Gourna Paleoudis E, Alaoui A, Lev-Ari S, Adams S, Kaufman J, Parikh SB, Tonti E, Muller E, Serzan M, Cheruku D, Lee A, Sridhar A, Hee BTP, Ahn J, Pecora A, Ip A, Atkins MB. Shah NJ, et al. Among authors: ip a. Cancers (Basel). 2024 Jun 14;16(12):2223. doi: 10.3390/cancers16122223. Cancers (Basel). 2024. PMID: 38927928 Free PMC article.
Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in <I>de novo</I> large B-cell lymphoma and transformed low-grade B-cell lymphoma.
Benjamini O, Fried S, Shouval R, Flynn JR, Beyar-Katz O, Leslie LA, Zucherman T, Yerushalmi R, Shem-Tov N, Palomba ML, Danylesko I, Sdayoor I, Malka H, Itzhaki O, Suh H, Devlin SM, Marcus R, Dahi PB, Jacoby E, Shah GL, Sauter CS, Ip A, Perales MA, Nagler A, Shimoni A, Scordo M, Avigdor A. Benjamini O, et al. Among authors: ip a. Haematologica. 2024 Nov 1;109(11):3566-3577. doi: 10.3324/haematol.2023.284664. Haematologica. 2024. PMID: 38899351 Free PMC article.
186 results